Intersect ENT Inc (XENT) Position Lifted by William Blair Investment Management LLC

William Blair Investment Management LLC boosted its holdings in shares of Intersect ENT Inc (NASDAQ:XENT) by 17.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,614 shares of the medical equipment provider’s stock after buying an additional 40,151 shares during the period. William Blair Investment Management LLC owned approximately 0.88% of Intersect ENT worth $7,751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. UBS Group AG increased its holdings in shares of Intersect ENT by 81.1% in the first quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after purchasing an additional 2,096 shares during the period. PNC Financial Services Group Inc. increased its holdings in shares of Intersect ENT by 2,091.8% in the second quarter. PNC Financial Services Group Inc. now owns 6,707 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 6,401 shares during the period. Cubist Systematic Strategies LLC increased its holdings in shares of Intersect ENT by 322.1% in the second quarter. Cubist Systematic Strategies LLC now owns 12,519 shares of the medical equipment provider’s stock valued at $469,000 after purchasing an additional 9,553 shares during the period. MetLife Investment Advisors LLC increased its holdings in shares of Intersect ENT by 22.2% in the second quarter. MetLife Investment Advisors LLC now owns 13,971 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 2,537 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of Intersect ENT by 10.1% in the first quarter. Principal Financial Group Inc. now owns 16,564 shares of the medical equipment provider’s stock valued at $651,000 after purchasing an additional 1,524 shares during the period. 91.66% of the stock is currently owned by institutional investors.

In other news, CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $28.92, for a total value of $371,130.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $30.01, for a total value of $600,200.00. The disclosure for this sale can be found here. Insiders sold 85,666 shares of company stock worth $2,505,926 in the last 90 days. Company insiders own 5.90% of the company’s stock.

Shares of XENT stock opened at $30.10 on Friday. The stock has a market capitalization of $899.24 million, a PE ratio of -53.75 and a beta of 0.58. Intersect ENT Inc has a fifty-two week low of $25.15 and a fifty-two week high of $42.95.

Intersect ENT (NASDAQ:XENT) last issued its earnings results on Monday, November 5th. The medical equipment provider reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. The firm had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.09 million. During the same quarter in the prior year, the business earned ($0.15) earnings per share. The company’s revenue was up 10.8% compared to the same quarter last year. Sell-side analysts anticipate that Intersect ENT Inc will post -0.73 EPS for the current fiscal year.

A number of brokerages have recently weighed in on XENT. Zacks Investment Research raised Intersect ENT from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a report on Wednesday, November 7th. BidaskClub raised Intersect ENT from a “sell” rating to a “hold” rating in a report on Thursday, October 11th. Northland Securities reissued a “hold” rating and issued a $28.00 price objective on shares of Intersect ENT in a report on Wednesday, October 17th. Finally, ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $37.17.

TRADEMARK VIOLATION WARNING: “Intersect ENT Inc (XENT) Position Lifted by William Blair Investment Management LLC” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/07/intersect-ent-inc-xent-position-lifted-by-william-blair-investment-management-llc.html.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Article: What is systematic risk?

Want to see what other hedge funds are holding XENT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intersect ENT Inc (NASDAQ:XENT).

Institutional Ownership by Quarter for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply